The main aim of the PhD in "NETWORK ONCOLOGY AND PRECISION MEDICINE" is to train researchers with an innovative profile, able to carry out autonomous experimental and clinical research in the field of personalized medicine in oncology.
This will be achieved through the offer of a multidisciplinary theoretical-practical, experimental and clinical training course, which will allow PhD students to learn the most updated laboratory, computational, diagnostic and clinical studies methods and integrate them for the fulfilment of research projects aimed at classifying, diagnosing, planning treatments and identifying prevention plans in oncology.
The PhD program offers interdisciplinary training for graduates in medicine, biology and in the disciplines included in the scientific-technological area. PhD students will acquire expertise in biomedical research that involves the integration of pathological-molecular and clinical data of each patient through the Network Medicine approach applied to oncology.
The research projects developed during the PhD training course will be multidisciplinary in the field of neoplastic pathologies and will have to transform the therapeutic intervention from the Top Down approach (1 pathology-1 therapy) to the Bottom-up approach (1 patient-1 therapy) through the identification of the clinical and molecular peculiarities of each patient (personalized medicine) and of complex molecular targets (precision medicine).
The scientific collaboration with outstanding researchers and excellent institutions will lead to an international training and scientific production characterized by the integration of molecular and clinical data in the oncological field, a feature of the PhD program that will provide PhD students a multidisciplinary and international teaching with mobility periods.
The institutions involved in the PhD training program in addition to the Sapienza University of Rome are:
Italian Institutions: Istituto Superiore di Sanità, Rome; Università di Napoli Federico II, Naples; Ospedale Pediatrico Bambino Gesù di Roma, Rome; Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola – Malpighi, Bologna; Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples.
E.U. Institutions: Max Delbrück Center (MDC) Berlin - Germany; University of Liverpool - United Kingdom; Charité - University Medicine Berlin - Germany; German Cancer Research Center (DKFZ), Heidelberg University - Germany; Glycomic Centre, Department of Cellular and Molecular Medicine, University of Copenhagen – Denmark; Institute of Molecular pathology and immunology of the University of Porto, Portugal; Department of Pharmacology and Personalised Medicine, Faculty of Health, Medicine and Life Science, Maastricht University, The Netherlands.
US: Weill Cornell Medical College New York, USA; Brigham and Women's Hospital of Harvard University, USA. |